The estimated Net Worth of Mark Alvino is at least 396 千$ dollars as of 17 June 2024. Mark Alvino owns over 25,890 units of Abeona Therapeutics Inc stock worth over 206,416$ and over the last 9 years Mark sold ABEO stock worth over 189,141$.
Mark has made over 6 trades of the Abeona Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Mark sold 25,890 units of ABEO stock worth 116,764$ on 17 June 2024.
The largest trade Mark's ever made was selling 35,000 units of Abeona Therapeutics Inc stock on 6 June 2022 worth over 5,600$. On average, Mark trades about 6,345 units every 49 days since 2016. As of 17 June 2024 Mark still owns at least 36,926 units of Abeona Therapeutics Inc stock.
You can see the complete history of Mark Alvino stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is 6555 CARNEGIE AVE, 4TH FLOOR, , CLEVELAND, OH, 44103.
Over the last 15 years, insiders at Abeona Therapeutics Inc have traded over 4,486,735$ worth of Abeona Therapeutics Inc stock and bought 427,809 units worth 1,765,143$ . The most active insiders traders include Capital Partners Llc Rouhan...、Todd Wider、Michael Amoroso. On average, Abeona Therapeutics Inc executives and independent directors trade stock every 50 days with the average trade being worth of 256,542$. The most recent stock trade was executed by Mark Alvino on 17 June 2024, trading 25,890 units of ABEO stock currently worth 116,764$.
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Abeona Therapeutics Inc executives and other stock owners filed with the SEC include: